Viking Therapeutics (VKTX) EBIT (2014 - 2026)

Viking Therapeutics has disclosed EBIT across 13 years of filings, most recently posting -$164.1 million for Q1 2026.

• EBIT for Q1 2026 came in at -$164.1 million, down 195.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$502.0 million (down 191.32% YoY), and the FY2025 annual result was -$393.3 million, down 160.63% from the prior year.
• EBIT came in at -$164.1 million for Q1 2026 at Viking Therapeutics, roughly flat from -$164.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$16.2 million in Q3 2022 to a low of -$164.7 million in Q4 2025.
• The 5-year median for EBIT is -$34.1 million (2024), against an average of -$51.7 million.
• Across the five-year window, EBIT decreased 13.45% in 2022 and tumbled 256.28% in 2025, its largest moves.
• Viking Therapeutics' EBIT stood at -$20.3 million in 2022, then tumbled by 44.38% to -$29.3 million in 2023, then plunged by 57.89% to -$46.2 million in 2024, then sank by 256.28% to -$164.7 million in 2025, then increased by 0.37% to -$164.1 million in 2026.
• The last three EBIT figures came in at -$164.1 million (Q1 2026), -$164.7 million (Q4 2025), and -$98.6 million (Q3 2025), per Business Quant data.